BRK-B — Berkshire Hathaway Inc.

As of 2026-08-27, the tape is not showing strong conviction in either direction. Q2 2026 operating earnings rose 16.3% YoY and Q2 revenue jumped to $101.8B on OxyChem/BHE/BNSF strength, but insurance underwriting earnings fell 13.1% and investment income fell 9.1%. Analyst ratings are 4 buy / 6 hold, and the consensus target of $465.50 is roughly 8% below the $503.70 price, keeping sentiment neutral.

Revenue was remarkably stable in the $90-95B range across 2023-2025, then inflected upward in Q2 2026 to $101.8B, a 10.0% YoY increase. Operating income has stair-stepped higher from roughly $13B in early 2023 quarters to $17.5B in Q2 2026, with Q2 2026 operating income up 12.3% YoY. GAAP net income is very noisy due to investment gains and losses: quarterly EPS swings from -$5.88 in Q3 2023 to +$17.36 in Q4 2023 and +$11.91 in Q2 2026. Underneath the noise, the operating trend is modestly accelerating, with insurance underwriting the clear weak spot.

As of 2026-08-27, valuation is fair-to-rich rather than cheap. TTM P/E is 12.7x on reported EPS of $39.81, above the 5-year average of 10.7x. P/S is 2.82x vs the 5-year average of 2.48x, while P/B is 1.45x, near the 5-year median of 1.48x. The catch is that reported earnings include large investment gains; on next-FY consensus operating EPS of $22.18, the forward multiple is about 22.7x. So it is not cheap on operating earnings, and only roughly fair on book value.

As of 2026-08-27, the market is paying up for the Abel-era capital deployment story, not for a beaten-down recovery. The current price embeds an assumption that cash can be put to work in high-return assets like the new ~$37B Alphabet stake and that OxyChem/BHE/BNSF will keep growing. If you normalize to operating EPS near $22, the market is effectively paying a premium for future reinvestment and the equity portfolio. The $465-475 zone is the support/mean-reversion band based on consensus targets and historical P/S; a decisive break above $537 would require Q3 operating EPS to accelerate meaningfully.

As of 2026-08-27, RSI was 49.46 - neutral, not overbought or oversold. Price was 1.09% below its 20-day SMA (~$509), 0.45% above its 50-day SMA (~$501), and 2.3% above its 200-day SMA (~$492). This is a range-bound consolidation pattern rather than a trending move. Entry timing is not urgent; support sits near the 200-day SMA around $492, with more serious support near the $465-475 valuation zone.

• Falling short-dated Treasury yields are compressing Berkshire's insurance investment income.
• BNSF freight volumes tie directly to US industrial demand and goods consumption.
• Energy and chemical prices affect OxyChem, BHE, and Chevron-related earnings.
• Regulatory/antitrust scrutiny of mega-cap tech creates headline risk for the new Alphabet stake.
• Auto insurance pricing and claims inflation drive GEICO's underwriting cycle.

• Q3 2026 earnings, expected early November 2026, for a cleaner read on GEICO underwriting and BHE/BNSF momentum.
• Mid-November 2026 13F filing to confirm whether Berkshire expanded its Alphabet stake or further shifted the equity portfolio.
• Continued cash deployment under Greg Abel - additional M&A or large equity purchases would signal confidence.
• A move in Treasury yields that changes the income contribution from Berkshire's cash and fixed-income portfolio.

• The new ~$37B Alphabet stake adds mega-cap tech concentration and multiple-compression risk.
• Insurance underwriting deterioration, with Q2 after-tax underwriting earnings down 13.1%, could worsen if claims inflation accelerates.
• OxyChem integration and energy/chemical margin cyclicality introduce execution and commodity risk.
• Valuation risk: the stock trades above the consensus target and above its own historical P/S/P/E averages, leaving limited margin of safety.

Berkshire remains a high-quality, conservatively financed compounder, but at $503.70 the stock is not offering a margin of safety. Operating momentum is real, but the market is already paying a premium for it, so the risk/reward is balanced rather than compelling. I would hold rather than chase, and revisit on a pullback toward the $465-475 zone or on evidence that operating EPS is accelerating above consensus.

Fair value triangulates three historical anchors: 5-year average P/S of 2.48x applied to forward revenue/share of roughly $187 gives ~$464; 5-year average P/E of 10.69x applied to reported TTM EPS of $39.81 gives ~$426; and median P/B of 1.48x applied to Q2 2026 book value/share of roughly $348 gives ~$515. Because reported EPS is distorted by investment gains, I weight the P/S and P/B legs more heavily, landing on $468.